Exclusive: Relmada CEO says his recent buy reflects ’significant undervaluation’

Investing.com -- Shares of small-cap biotech Relmada Therapeutics Inc (NASDAQ: RLMD) have surged over the past week as insider buying sparked renewed investor interest.

The stock has more than doubled since August 27, after CEO Sergio Traversa disclosed the open-market purchase of 265,976 shares between August 26–28, 2025, at prices ranging from $0.62 to $0.74. The transaction, valued at more than $178,000, lifted his direct ownership to 1,000,000 shares.

Adding to the momentum, Chief Medical Officer–Urology, Raj S. Pruthi, MD, reported on August 29 that he had purchased 55,000 shares of the company’s common stock.

Relmada shares, which closed at $0.67 on August 27, have since soared to $1.44 - a 115% gain.

In exclusive comments to Investing.com, Traversa said the move underscores his belief that the market is undervaluing the company.

"I have purchased an additional 260,000 shares of Relmada common stock, increasing my holdings to 1,000,000 shares, all acquired with personal funds,” the CEO said. “My decision to make this substantial additional investment reflects my strong conviction that Relmada remains significantly undervalued by the market. I am extremely confident in our company’s innovative pipeline, strategic direction, and exceptional long-term growth potential.”

He added, “As CEO, I am committed to creating substantial value for all shareholders, and this investment aligns my interests directly with those of our investor community."

Investors appear to be following his lead. Since Traversa’s Form 4 filing after the market close on August 28, trading volume has exploded. The stock has averaged more than 8.25 million shares traded per day over the past three sessions compared with a typical average of just 650,000.

You May Also Be Interested In

• Citi opens downside catalyst watch on Kroger as Walmart price war intensifies
• Tim Cook’s final day today: What the $4.67T handoff means for Apple investors
• Goldman Sachs starts Viridien at Buy on exploration recovery, shares rise